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Bacteraemia is a common cause of fever among 
patients presenting to hospitals in sub-Saharan Africa 
(SSA), but it remains underdiagnosed because many 
facilities lack the proper resources, and it often 
presents in nonspecific ways.[1] Furthermore, the 
worldwide rise of antibiotic resistance makes empirical therapy 
increasingly difficult, especially in resource-limited settings.[2,3] 
Maputo Central Hospital (MCH) is a 1  200-bed national referral 
hospital in Maputo, the capital of Mozambique. It is the principal 
teaching hospital in Mozambique, in collaboration with Universidade 
Eduardo Mondlane (UEM). MCH has a modern, automated system 
in place to perform blood cultures and diagnose bacteraemia, yet 
historically the system was underutilised. We designed a prospective 
study to determine the incidence of bacteraemia in patients presenting 
with fever, a common presenting sign in the medical wards of MCH. 
The majority of patients admitted to the medical wards at MCH 
are HIV-positive, commonly presenting in late stages of disease, 
and not on antiretroviral therapy. This is consistent with other 
reports from Mozambique and the greater region.[4,5] The differential 
diagnosis for fever is broad in this population and frequently includes 
bacteraemia,[1,6-8] although it was rarely considered at MCH prior to 
this study.
The greater context of this study is the Medical Education 
Partnership Initiative between the University of California, San 
Diego, USA, and UEM, which focuses on strengthening the 
educational and research infrastructure of Mozambique’s three 
public medical schools. A major priority of this collaboration is to 
recruit trainees and junior faculty into lifelong careers in medical 
education and research while providing them with the skills to make 
these careers sustainable.[9,10] At the outset of the collaboration, 
doctors working in the internal medicine department at MCH 
were surveyed in order to identify problems considered to be of 
highest importance. ‘We are blind’ was a specific phrase repeated 
by numerous doctors in this survey, in reference not only to their 
limited diagnostic resources but also to the lack of medical research 
done locally. Early efforts to address these problems included 
implementation of a regular schedule of clinical conferences and 
journal clubs in the residency training programme, accompanied 
by improved access to internet and medical information in the 
hospital, in order to establish a culture of scientific enquiry and 
evidence-based medicine. Focus later shifted to improvement 
of biomedical informatics, as well as infrastructure for clinical, 
operational and epidemiological research. Opportunities for 
Mozambican medical residents to participate in research projects 
were sought. This study is the first to be carried out in part by 
residents in the internal medicine training programme at MCH. It 
also represents the first study of bacteraemia in a hospitalised adult 
Mozambican population.
In addition to describing the incidence of bacteraemia in febrile 
adults presenting to MCH and creating an antibiogram, we set out 
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to describe the antibiotic prescribing habits of local doctors and to 
identify links with patient outcomes, with a view to identifying high-
yield areas for future quality improvement projects.
Methods 
Ethical statement
Ethical approval was obtained specifically for this study from the 
University of California, San Diego Institutional Review Board as well 
as the Mozambican National Committee for Bioethics and Health.
Study team
We assembled a study team of local Mozambican healthcare workers: 
a nurse who enrolled and phlebotomised patients, five internal 
medicine residents who recorded patient clinical information and 
outcomes, a microbiology laboratory technician charged with 
processing blood cultures, and a senior infectious disease expert. In 
addition, there were two collaborators from the USA, one on-site and 
one off-site.
Patient enrolment
From September 2011 through October 2012, and then again 
from July 2013 through March 2014, the study nurse enrolled 
patients on weekday mornings from the internal medicine wards. 
Inclusion criteria were as follows: (i) ≥18 years of age; (ii) axillary 
temperature ≥38°C or ≤35°C; (iii) admission in the past 24 hours; 
and (iv) no receipt of antibiotics as an inpatient. Each patient gave 
written informed consent. If patients were unable to give consent, 
an attendant (usually a family member) consented for them. We 
initially attempted to enrol patients from the emergency room, which 
was frequently overcrowded and understaffed, but abandoned these 
efforts out of concern for patient safety and a desire to not influence 
emergency room doctors’ decisions to admit patients. Once enrolled, 
the nurse drew 20 mL of blood from each patient and aseptically 
inoculated two BacT/Alert aerobic blood culture bottles (bioMérieux, 
France).
Data collection
The in-hospital medical team was responsible for all clinical decisions 
regarding patient management. Each patient was independently 
followed by one of the Mozambican internal medicine residents on 
the study team, who recorded laboratory data as well as outcomes 
‘improved’, ‘unimproved’ or ‘died’ from patient charts. Members of 
the study team did not make clinical decisions but did inform the 
doctors caring for the patient that their patient had been enrolled in 
a study and facilitated communication of blood culture results from 
the laboratory. Nonetheless, in some cases patients were discharged 
before a complete data set had been recorded. Each team member 
received an Android tablet with a customised Health Information 
System application (keep.distributedhealth.org) for data entry. Data 
were synchronised automatically from tablets to a server when 
internet was available. An offsite US collaborator reviewed data on a 
weekly basis and debriefed the study team.
Bacterial culture, identification and antibiotic 
susceptibility testing
Blood cultures were processed using BacT/Alert i AST bottles in 
a BacT/ALERT 3D machine (bioMérieux). Isolates from positive 
cultures were identified by standard biochemical tests as set out in 
Clinical Laboratory Standards Institute (CLSI) guidelines.[11] Cultures 
were considered contaminated if they grew coagulase-negative 
Staphylococcus or diptheroids. Antimicrobial susceptibility testing 
was performed by standard disc diffusion methods to trimethoprim/
sulfamethoxazole (1.25/23.75 μg), chloramphenicol (30 μg), oxacillin 
(1 μg), penicillin (10 μg), ampicillin (10 μg), tetracycline (30 μg), 
gentamicin (10 μg) ceftriaxone (30 μg), ciprofloxacin (5 μg) and 
imipenem (10 μg). Phenotypic methicillin-resistant Staphylococcus 
aureus (MRSA) were determined by oxacillin disc and cefoxitin 
disc and tested for resistance to vancomycin. In Salmonella isolates, 
antibiotic susceptibilities were also confirmed using the Vitek-
II system (Card AB AST-N156, bioMérieux). Isolates flagged as 
extended-spectrum β-lactamase (ESBL) or demonstrating resistance 
to ceftriaxone or ceftazidime by the disc diffusion method were 
phenotypically confirmed by the combined double-disc method 
using ceftazidime and cefepime alone and in combination with 
clavulanic acid. Breakpoints for resistance were according to CLSI 
guidelines.[11]
Clinical laboratory data
Clinical laboratory data relevant to this study were processed in 
five different laboratories. For patients who did not have clearly 
documented HIV status, a rapid test was performed using both 
the Determine HIV1/2 Rapid Test (Abbot Laboratories, USA) and 
the Unigold HIV Rapid Test (Trinity Biotech, Ireland). Per hospital 
protocol, in the case of discordant results both tests were repeated 
in one month (there is no third test available as a tiebreaker at 
MCH). CD4 counts were determined using a FACS-Calibur flow 
cytometer (BD Biosciences, USA). Complete blood counts were 
determined with an XE-2100 haematology analyser (Sysmex, 
Japan). Plasmodium falciparum malaria was diagnosed first with 
a rapid immunochromatographic test for the HRP-2 antigen (First 
Response, Premiere Medical Corporation, India); if positive, a 
Giemsa-stained thick and thin smear was analysed in the regular 
course of clinical duty by a locally trained microscopist paid by the 
Ministry of Health. In cases where sputum smears were ordered, 
Ziehl-Neelsen-stained slides were similarly interpreted by a hospital 
microscopist. Owing to limited resources, we were not able to 
implement quality control for microscopy-based diagnoses, and our 
data reflect what was available to Mozambican doctors charged with 
caring for enrolled patients.
Statistical analysis
Data were exported from the online database to an Excel spread-
sheet. Descriptive statistics were calculated with Excel and further 
analysis was done with free online software (vassarstats.net). 
Categorical data were compared with the χ2 test and Fisher’s exact 
test where appropriate. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated for clinical predictors of bacteraemia, 
and clinical predictors for poor outcomes (‘unimproved’ or ‘died’) in 
patients with bacteraemia. In cases where specific clinical variables 
or outcomes were not available for all patients, only those patients for 
whom the variables were known were used in the analysis. Two-tailed 
p-values of <0.05 were considered statistically significant.
Results
Of the 841 patients enrolled, 63 (7.5%) had a bloodstream infection. 
Of the 765 (91.1%) patients with a documented outcome, 138 (18.0%) 
died while in the hospital.
Thirteen of 56 (23.2%) patients with bacteraemia and a 
documented outcome died while in the hospital, but bacteraemia 
was not a significant predictor of in-hospital mortality (OR 1.41; 
95% CI 0.74 - 2.70; p=0.37). However, bacteraemia was significantly 
linked to the combined endpoint of ‘died’ and ‘unimproved’ 
as a hospital outcome (OR 1.89; 95% CI 1.07 - 3.39; p=0.03). 
Characteristics of the patient population and associations with 
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bacteraemia are set out in Table  1. There 
were very few factors associated with 
bacteraemia with a p-value <0.20, so a 
multi factorial analysis was not done.
Fifty blood cultures (5.9%) were considered 
to be contaminants. The most common 
pathogenic isolates were S. aureus, E. coli 
and non-typhoidal Salmonella (NTS) (Table 
2). Eight of 17 S. aureus isolates (47.0%) 
were MRSA, consistent with local hospital 
epidemiology, and these had variable 
susceptibility to co-trimoxazole, tetracycline, 
chloramphenicol and ciprofloxacin. All 
Gram-positive isolates were sensitive to 
vancomycin. Of 35 Gram-negative isolates, 
10 (28.6%) were resistant to ceftriaxone and 
6 (17.1%) to ciprofloxacin. All S. typhimurium 
isolates were resistant to chloramphenicol, 
ampicillin and co-trimoxazole, and 4 of 
10 (40.0%) had an ESBL phenotype. Two 
Enterobacter spp., one Klebsiella pneumoniae 
and one E. coli also had an ESBL phenotype 
(Table 2). All non-Salmonella Gram-negative 
isolates were sensitive to gentamicin.
Patients with bloodstream infection 
received empirical antibiotics with a 
spectrum broad enough to cover their 
infecting organism in 20/59 cases (33.9%). 
Among patients who had bacteraemia, 
those who received ineffective empirical 
antibiotics were more likely to have a poor 
clinical outcome (OR 8.05; 95% CI 1.62  - 
39.91; p=0.04) (Table 3). Of all patients, 
597 (71.0%) were prescribed empirical 
antibiotics by the admitting teams. A total 
of 50 different empirical antibiotic regimens 
were used. Penicillin was the single antibiotic 
most often prescribed. Combination therapy 
Table 1. Characteristics of study population (N=841) and predictors of bloodstream infection*
Characteristic
Bloodstream infection
OR (95%CI) p-valueYes, n (%) No, n
Male (N=425) 35 (8.2) 390 1.20 (0.72 - 2.00) 0.52
Female (N=416) 29 (7.0) 387 0.84 (0.50 - 1.39) 0.52
SIRS† (N=663) 50 (7.5) 613 0.658 (0.36 - 1.21) 0.23
No SIRS† (N=136) 15 (11.0) 121 1.52 (0.83 - 2.79) 0.23
SBP ≤90 mmHg (N=90) 12 (13.3) 78 1.84 (0.94 - 3.56) 0.06
SBP >90 mmHg (N=658) 53 (8.1) 635 0.54 (0.28 - 1.06) 0.06
Hb <5 mg/dL (N=98) 18 (18.4) 80 1.78 (0.98 - 3.23) 0.06
Hb ≥5 mg/dL (N=660) 47 (7.1) 372 0.56 (0.31-1.02) 0.06
HIV+ (N=652) 55 (8.4) 597 1.07 (0.53 - 2.16) 1.0
HIV– (N=126) 10 (7.9) 116 0.94 (0.46 - 1.89) 1.0
CD4 <200 cells/µL‡ (N=382) 25 (6.8) 357 0.93 (0.42 - 2.04) 1.0
CD4 >200 cells/µL‡ (N=128) 9 (7.0) 119 1.08 (0.49-2.38) 1.0
HIV+ on ARVs (N=263) 24 (9.1) 239 0.80 (0.46 - 1.41) 0.48
HIV+ not on ARVs (N=279) 31 (11.1) 248 1.24 (0.71 - 2.18) 0.48
HIV+ on TMP-SMX 
prophylaxis (N=453)
34 (7.5) 419 0.69 (0.39-1.22) 0.22
HIV+ without TMP-SMX 
prophylaxis (N=199)
21 (10.5) 178 1.45 (0.82 - 2.57) 0.22
SIRS = systemic inflammatory response syndrome; SBP = systolic blood pressure; Hb = haemoglobin; ARVs = antiretrovirals; 
TMP-SMX = trimethoprim-sulfamethoxazole.
*Owing to missing data, not all n’s in each category add up to total N.
†SIRS defined as at least two of the following: axillary temperature ≥38°C, heart rate >90 bpm, respiratory rate >20/min, and 
white cell count <4 × 109cells/L or >11 × 109cells/L.
‡Data available for 34 of 55 HIV+ patients with bacteraemia.
Table 2. Incidence of specific pathogens causing bloodstream infections, and corresponding antibiogram
Gram-positive organisms, % susceptibility n PCN AMP OX VAN TCN SXT CAM CIP CTX
S. aureus 17 0 0 53 100 71 65 76 65 53
S. pneumoniae 3 67 67 100 100 67 67 100 0 100
Enterococcus spp. 2 50 100 0 100 0 N/A 50 0 0
S. agalactiae 1 100 100 100 100 100 100 100 0 100
S. pyogenes 1 100 100 100 100 100 100 100 0 100
Overall susceptibility 24 17 25 58 100 67 67 79 46 58
Gram-negative organisms, % susceptibility n AMP TCN CAM SXT CIP GEN CTX IPM
S. typhimurium 9 0 67 0 0 89 N/A 55 100
S. enteritidis 1 100 100 100 100 100 N/A 100 100
E. coli 14 21 7 43 57 86 100 93 100
K. pneumoniae 4 0 75 50 75 100 75 100
Enterobacter spp. 2 0 0 0 0 50 100 0 100
Citrobacter freundii 1 0 0 0 0 100 100 100 100
Proteus vulgaris 1 100 100 100 100 100 100 100 100
Morganella morganii 1 0 0 100 0 100 100 100 100
Acinetobacter baumanii 1 0 0 0 0 0 100 0 100
Pseudomonas aeruginosa 1 0 0 0 0 100 100 0 100
Overall susceptibility 35 14 0 26 31 83 71 71 100
PCN = penicillin; AMP = ampicillin; OX: oxacillin; VAN = vancomycin; TCN = tetracycline; SXT = co-trimoxazole; CAM = chloramphenicol; CIP = ciprofloxacin; CTX: ceftriaxone;  
GEN = gentamicin; IPM = imipenem; N/A = not applicable.
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with oral antibiotics was common. Hospital 
doctors adjusted empirical antibiotics before 
discharge in 153/597 cases (25.6%). There 
was no commonly used empirical antibiotic 
regimen that had >80% coverage against all 
collected isolates. Overall, 20/59 (33.9%) 
of all bacterial isolates showed resistance 
to ceftriaxone, the broadest-spectrum anti-
biotic commonly available at MCH. The 
spectrums of several antibiotic regimens 
potentially available at MCH are shown in 
Table 4. It should be noted that vancomycin 
and imipenem were rarely used by doctors 
and are not readily available at MCH.
In only 4/59 cases of bloodstream infec tion 
(6.8%) was the diagnosis of bacteraemia or 
sepsis recorded in the chart at discharge. 
The most common diagnosis obtained from 
medical records was tuberculosis, accounting 
for >25% of all patients. Tuberculosis was 
usually diagnosed empirically; in only 13.5% 
of cases was there a positive smear, and 
cultures were virtually never done. HIV was 
recorded as the sole diagnosis for 23.1% 
of enrolled patients. Eleven patients with 
bacteraemia were diagnosed as having 
tuberculosis.
Discussion
As has been reported at other hospitals 
in SSA, bacteraemia is a common cause 
of fever at MCH, accounting for nearly 
8% of all cases of fever in patients newly 
admitted to the internal medicine wards. 
That it was not a significant risk factor 
for in-hospital mortality largely reflects 
the severity of illness and consequent high 
mortality rate of patients admitted to MCH. 
Furthermore, we were not able to follow 
up patients after discharge, so the 30-day 
mortality rate for patients with bacteraemia 
was probably higher. The predominance of 
S. aureus was not surprising, although most 
studies in the region report NTS to be more 
common than E. coli as a cause of invasive 
disease.[1] NTS was the most common 
isolate from febrile patients during the first 
period (September 2011 - October 2012), 
but dropped off significantly in the second 
period (July 2013 - March 2014), being 
surpassed by E. coli and S. aureus. The vector 
and routes of transmission for NTS in SSA 
are largely unknown; it is possible that some 
environmental factor during the time we 
were collecting specimens affected the NTS 
incidence. Several factors may account for 
the low number of Streptococcus pneumoniae, 
expected to be higher based on other 
regional reports.[1] Although no patients 
enrolled in this study were documented to 
have received antibiotics at MCH before 
having their blood cultures drawn, as MCH 
is a referral centre, many patients may have 
received antibiotics at peripheral hospitals 
before transfer. Antibiotic use is widespread 
in the community, as in other developing 
countries,[12] and it may simply be that most 
patients with invasive S. pneumoniae are 
treated before presenting at MCH. These 
factors may have decreased the overall rate 
of bacteraemia in this study, or selected for 
a sample with a higher resistance rate than 
that of the community.
Antibiotic resistance was common in the 
bloodstream pathogens we isolated. Nearly 
half of the S. aureus isolates were MRSA 
Table 3. Predictors of poor outcomes in patients with bacteraemia*
Predictor, n (total 
N=59)*
Outcome
OR (95% CI) p-value
Unimproved 
or died, n (%) Improved, n (%)
Incorrect empirical 
antibiotics (N=36)
17 (47.2) 19 (52.8) 8.05 (1.62 - 39.91) 0.004
Correct empirical 
antibiotics (N=20)
2 (10.0) 18 (90.0) 0.12 (0.03 - 0.62) 0.004
HIV+ (N=45) 11 (24.4) 34 (75.6) 0.75 (0.17 - 3.43) 0.99
HIV– (N=10) 3 (30.0) 7 (70.0) 1.32 (0.29 - 6.02) 0.99
HIV+ on ARVs 
(N=21)
6 (28.6) 15 (71.4) 0.74 (0.20 - 2.78) 0.74
HIV+ not on ARVs 
(N=20)
7 (35.0) 13 (65.0) 1.34 (0.36 - 5.04) 0.74
SBP ≤90 mmHg 
(N=10)
6 (60.0) 4 (40.0) 2.0 (0.46 - 8.70) 0.29
SBP >90 mmHg 
(N=38)
12 (31.6) 26 (68.4) 0.5 (0.115 - 2.17) 0.29
SIRS (N=40) 10 (25.0) 30 (75.0) 0.67(0.14 - 3.17) 0.68
No SIRS (N=9) 3 (33.3) 6 (66.7) 1.5 (0.32 - 7.14) 0.68
Salmonella 
bacteraemia (N=10)
2 (20.0) 8 (80.0) 0.43 (0.08 - 2.25) 0.47
Non-Salmonella 
bacteraemia (N=46)
17 (37.0) 29 (63.0) 2.34 (0.45 - 12.34) 0.47
S. aureus 
bacteraemia (N=17)
6(35.3) 11 (64.7) 1.09 (0.33 - 3.61) 1.0
Non-S. aureus 
bacteraemia (N=39)
13 (33.3) 26 (66.7) 0.92 (0.28 - 3.03) 1.0
SBP = systolic blood pressure; SIRS = systemic inflammatory response syndrome.
*Cases of fungaemia (n=4) as opposed to bacteraemia were excluded from this analysis. Owing to missing data (5% of 
outcomes data, <5% of other variables), n for each characteristic does not add up to total N.
Table 4. Spectrum of antibiotic combinations available at MCH against bacteraemia isolates
Antibiotic regimen % covered Uncovered organisms
CTX alone 66 MRSA, ESBL GNRs
CTX + GEN 76 MRSA
CTX + CIP 75 MRSA* CIP-resistant GNRs
CTX + GEN + CIP 81 MRSA* CIP-resistant GNRs
VAN+CTX 83 ESBL GNRs
VAN+GEN 83 Salmonella
VAN+GEN + CIP 98 CIP-resistant Salmonella
VAN + IPM 100 None
IPM alone 85 MRSA
CTX = ceftriaxone; GEN = gentamicin; CIP = ciprofloxacin; VAN = vancomycin; IPM = imipenem.
*Several MRSA isolates in this study showed in vitro susceptibility to CIP, although caution is necessary in using CIP to treat  
S. aureus infections as resistance is known to occur rapidly.
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and resistant to all first-line antibiotics commonly used at MCH. 
More than 25% of all Gram-negative organisms had an ESBL 
phenotype. S. typhimurium, resistant to ampicillin, chloramphenicol 
and co-trimoxazole, is commonly reported in the region.[13,14] All 
S. typhimurium isolates described here showed this multidrug-
resistant phenotype, and 4 of 9 isolates had an ESBL phenotype in 
addition. This is the first report of invasive ESBL S. typhimurium 
in Mozambique. Unfortunately, even given this small sample size 
it appears that there is no simple empirical antibiotic regimen 
consisting of readily available antibiotics at MCH that will cover 
all the most common pathogens causing bacteraemia. Penicillin-
based regimens that are commonly used at MCH are inadequate. 
Ceftriaxone is used commonly, and was active against 71% of Gram-
negative rods (GNRs) reported here, but is ineffective against MRSA, 
which accounts for a significant portion of bacteraemia at MCH. 
Vancomycin was effective against 100% of Gram-positives collected 
in this study, but it is relatively expensive and in short supply at 
MCH, and therefore not recommended for widespread empirical 
use. However, these results underscore the value of vancomycin, and 
suggest that clearer local guidelines and an antibiotic stewardship 
programme at MCH could help to ensure its judicious use and save 
lives. Of the other readily available antibiotics, chloramphenicol 
has the best coverage of the MRSA reported here, but cannot be 
recommended for empirical use based on these data. The addition of 
ciprofloxacin to empirical regimens will expand the spectrum to cover 
most of the ESBL pathogens described here, and will also cover >50% 
of the MRSA, although S. aureus has been shown to acquire resistance 
to ciprofloxacin rapidly.[15] Gentamicin was effective against all non-
Salmonella GNRs, but empirical regimens in patients with suspected 
bacteraemia at MCH (particularly those with AIDS) must cover 
NTS, given local epidemiology. All GNRs isolated in the course of 
this study were susceptible to imipenem, which was not consistently 
available at MCH during the time of this study. These results support 
the argument for a well-monitored supply of carbapenem antibiotics. 
According to these data, if neither vancomycin nor imipenem (or 
other carbapenem antibiotics) are available, the empirical three-drug 
regimen offering the broadest spectrum at MCH is ceftriaxone + 
gentamicin + ciprofloxacin (81% coverage, Table 3), although this 
regimen was used infrequently during the time of this study.
There was wide variation in empirical antibiotic regimens 
prescribed to febrile patients in the medical wards at MCH, and 
inappropriate empirical choices were linked with bad outcomes. 
Empirical regimens were infrequently changed during the course 
of hospitalisation, reflecting an underutilisation of microbiology 
services at MCH, as well as problems with transmission of 
information between the laboratory and the wards. Given the rate 
of antibiotic resistance reported here, it is essential for physicians to 
maintain a high index of suspicion for bacteraemia, and for them to 
order blood cultures appropriately in febrile patients. The laboratory 
must also be able to provide information regarding positive blood 
cultures and antibiotic susceptibilities promptly, in order to guide 
subsequent antibiotic adjustment. It was frequently noted during the 
course of the study that patient follow-up and data completeness were 
hampered by paper records that were often incomplete, illegible or 
lost. These problems also affect reporting laboratory information and 
almost certainly affect clinical care and patient outcomes. Although 
our study team did not take part in the clinical care of patients, 
they made every effort to inform doctors when their patients had 
bacteraemia. A variety of factors such as poorly tracked patient 
transfers and chart movements, difficulty in contacting doctors 
charged with care for specific patients, and understaffing in the 
labs and on the wards meant that this was not always successful. As 
more hospitals in the developing world move from paper charts to 
electronic medical records, there is hope that these problems can be 
minimised and patient outcomes improved.
Conclusion
Patients admitted to MCH with bacteraemia have poor outcomes. 
This study highlights several opportunities for quality improvement, 
including educating physicians to have a higher index of suspicion 
for bacteraemia in patients with fever, improving local guidelines for 
empirical antibiotic therapy and improving communication between 
the microbiology laboratory and the clinicians, as well as increasing 
the supply of some key antibiotics such as vancomycin and imipenem.
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